Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to -$19000.0.

  • Collegium Pharmaceutical's Gains from Investment Securities fell 10012.19% to -$19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 8749.25%. This contributed to the annual value of $52.1 million for FY2024, which is 11520.35% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Gains from Investment Securities stood at -$19000.0, which was down 10012.19% from -$358000.0 recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Gains from Investment Securities registered a high of $23.0 million during Q2 2024, and its lowest value of -$2.9 million during Q4 2024.
  • Its 5-year average for Gains from Investment Securities is $5.3 million, with a median of $3.4 million in 2022.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 180413.22% in 2023, then plummeted by 14215.86% in 2024.
  • Collegium Pharmaceutical's Gains from Investment Securities (Quarter) stood at $2.3 million in 2021, then tumbled by 84.27% to $363000.0 in 2022, then surged by 1804.13% to $6.9 million in 2023, then crashed by 142.16% to -$2.9 million in 2024, then skyrocketed by 99.35% to -$19000.0 in 2025.
  • Its Gains from Investment Securities stands at -$19000.0 for Q3 2025, versus -$358000.0 for Q2 2025 and $10.6 million for Q1 2025.